Asset Allocation
Get Ready for a Biotech M&A Comeback
RBC Capital, heartened by some billion-dollar-plus deals, sees a new buyout hunger in Big Pharma.
TPR pressures French biopharmaceutical company to boost UK defined benefit plan funding.